CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES (Details 4) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Sep. 09, 2014
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments		$ 600,000
Estimated fair value of debt instruments
Reduction in basic and diluted net loss per share	$ (0.03)
2021 Notes
Estimated fair value of debt instruments
Interest rate (as a percent)	2.50%			2.50%
Principal amount	345,000,000		345,000,000	345,000,000
Level 3 | Contingent consideration
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Balance at the beginning of the period			17,595,000
Unfavorable contract assumed	1,777,000		3,343,000
Balance at the end of the period	16,496,000		17,595,000
Level 3 | Contingent consideration | Interest Expense.
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Change in fair value	219,000
Net accretion value adjustments	445,000
Level 3 | Contingent consideration | Selling general and administrative expense
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Change in fair value	(1,785,000)
Net accretion value adjustments	(1,544,000)
Level 3 | Contingent consideration | Zipsor
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Balance at the beginning of the period			1,800,000
Balance at the end of the period	1,760,000		1,800,000
Level 3 | Contingent consideration | Zipsor | Interest Expense.
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments	82,000
Level 3 | Contingent consideration | Zipsor | Selling general and administrative expense
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments	(122,000)
Level 3 | Contingent consideration | Lazanda
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Balance at the beginning of the period			11,209,000
Balance at the end of the period	11,617,000		11,209,000
Level 3 | Contingent consideration | Lazanda | Interest Expense.
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments	96,000
Level 3 | Contingent consideration | Lazanda | Selling general and administrative expense
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments	312,000
Level 3 | Contingent consideration | CAMBIA
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Balance at the beginning of the period			1,243,000
Balance at the end of the period	1,342,000		1,243,000
Level 3 | Contingent consideration | CAMBIA | Interest Expense.
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments	48,000
Level 3 | Contingent consideration | CAMBIA | Selling general and administrative expense
Changes in fair value of all financial liabilities measured at fair value on a recurring basis
Net accretion value adjustments	51,000
Fair Value | Level 2 | 2021 Notes
Estimated fair value of debt instruments
Estimated fair value of debt	$ 463,000,000		$ 375,200,000